View:
Mini BasicThis view is available after user registration.
ShortThis view is available when you buy a license.
StandardThis view is available when you buy a license.
CompleteThis view is available when you buy a license.
Nivolumab 240, Non-Small Cell Lung Cancer, Second Line
Protocol-ID: 598 V2.0 (Mini), NIVO240, NSCLC, second lineIndication(s)
- Lung Carcinoma, Non-Small Cell; ICD-10 C34.-
Links
- Nivolumab (opdivo) [EMA EPAR]
- Bristol-Myers Squibb’s Opdivo® (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing [URL]
 | The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti. |
Valid since: 12.06.2018